NSC 146109 hydrochlorideAntitumor agent,p53-dependent transcription activator CAS# 59474-01-0 |
- RETRA hydrochloride
Catalog No.:BCC2415
CAS No.:1036069-26-7
- Tenovin-1
Catalog No.:BCC2239
CAS No.:380315-80-0
- Pifithrin-α (PFTα)
Catalog No.:BCC2241
CAS No.:63208-82-2
- NSC 319726
Catalog No.:BCC2242
CAS No.:71555-25-4
- PhiKan 083
Catalog No.:BCC2411
CAS No.:880813-36-5
- JNJ-26854165 (Serdemetan)
Catalog No.:BCC2240
CAS No.:881202-45-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 59474-01-0 | SDF | Download SDF |
PubChem ID | 16759161 | Appearance | Powder |
Formula | C17H17ClN2S | M.Wt | 316.85 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in ethanol and to 100 mM in DMSO | ||
Chemical Name | (10-methylanthracen-9-yl)methyl carbamimidothioate;hydrochloride | ||
SMILES | CC1=C2C=CC=CC2=C(C3=CC=CC=C13)CSC(=N)N.Cl | ||
Standard InChIKey | VIBMUYOXJUCEMA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H16N2S.ClH/c1-11-12-6-2-4-8-14(12)16(10-20-17(18)19)15-9-5-3-7-13(11)15;/h2-9H,10H2,1H3,(H3,18,19);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Cell-permeable, genotype-selective antitumor agent that activates p53-dependent transcription. Increases levels of endogenous p53 in tumor cells and protects p53 from Mdm2-mediated degradation. Displays some selectivity for tumor cells vs. normal cells in an MTT cell viability assay. |
NSC 146109 hydrochloride Dilution Calculator
NSC 146109 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1561 mL | 15.7803 mL | 31.5607 mL | 63.1214 mL | 78.9017 mL |
5 mM | 0.6312 mL | 3.1561 mL | 6.3121 mL | 12.6243 mL | 15.7803 mL |
10 mM | 0.3156 mL | 1.578 mL | 3.1561 mL | 6.3121 mL | 7.8902 mL |
50 mM | 0.0631 mL | 0.3156 mL | 0.6312 mL | 1.2624 mL | 1.578 mL |
100 mM | 0.0316 mL | 0.1578 mL | 0.3156 mL | 0.6312 mL | 0.789 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
NSC 146109 hydrochloride is a selective activator of p53 with IC50 value ranges from 2.5 to >5 μg/mL [1].
Tumor protein p53 (p53) is a crucial protein in multicellular organisms and plays a pivotal role in preventing cancer formation. [1].
NSC 146109 hydrochloride is a potent p53 activator and has a higher activity than reported p53 activator RITA. When tested with breast tumor cell line MCF-7 cells, NSC 146109 hydrochloride treatment induced cell apoptosis and decreased cell viability through activating p53 expression which in turn up-regulated the expression of p21 [2]. In 16 tumor cells, NSC 146109 hydrochloride showed no clear genetic basis for the tumorigenic cell selectivity while had different affinity to different cell lines [1]. When tested with head and neck cancer (HNC) cell lines (high-expression of MDM4 while low-expression of p53, NSC 146109 hydrochloride treatment significantly suppressed cell growth and promoted cell apoptosis in a dose-dependent manner [3].
In mice model with head and neck cancer (HNC) cells subcutaneous xenograft, administration of NSC 146109 hydrochloride markedly inhibited cell growth and decreased tumor volume alone or combined with chemotherapy drug cisplatin which was regarded as a promising strategy for treating HNC in clinic [3].
References:
[1]. Dolma, S., et al., Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 2003. 3(3): p. 285-96.
[2]. Wang, H. and C. Yan, A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia, 2011. 13(7): p. 611-9.
[3]. Roh, J.L., J.Y. Park, and E.H. Kim, XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. Apoptosis, 2014. 19(11): p. 1594-602.
- Dihydropyrocurzerenone
Catalog No.:BCN8061
CAS No.:59462-26-9
- Nimbin
Catalog No.:BCN4617
CAS No.:5945-86-8
- Monotropein
Catalog No.:BCN6280
CAS No.:5945-50-6
- 1-Methyl-2-undecylquinolin-4(1H)-one
Catalog No.:BCN6591
CAS No.:59443-02-6
- 1F-Fructofuranosylnystose
Catalog No.:BCN8287
CAS No.:59432-60-9
- Boc-HoSer(Bzl)-OH
Catalog No.:BCC3244
CAS No.:59408-74-1
- Darutigenol
Catalog No.:BCN4096
CAS No.:5940-00-1
- PIK-93
Catalog No.:BCC2519
CAS No.:593960-11-3
- Alizapride HCl
Catalog No.:BCC4618
CAS No.:59338-87-3
- Triacontanol
Catalog No.:BCC8260
CAS No.:593-50-0
- Lindleyin
Catalog No.:BCN8450
CAS No.:59282-56-3
- Vitexin 2''-O-p-coumarate
Catalog No.:BCN2793
CAS No.:59282-55-2
- Tafamidis
Catalog No.:BCC5268
CAS No.:594839-88-0
- Z-D-Glu(OBzl)-OH
Catalog No.:BCC2772
CAS No.:59486-73-6
- Citric acid monohydrate
Catalog No.:BCN8492
CAS No.:5949-29-1
- Testosterone undecanoate
Catalog No.:BCC9173
CAS No.:5949-44-0
- Calycanthine
Catalog No.:BCN7823
CAS No.:595-05-1
- Soyasapogenol B
Catalog No.:BCN4097
CAS No.:595-15-3
- Megestrol Acetate
Catalog No.:BCC4365
CAS No.:595-33-5
- Boc-Ser-OBzl
Catalog No.:BCC3440
CAS No.:59524-02-6
- H-D-Ala-OtBu.HCl
Catalog No.:BCC2849
CAS No.:59531-86-1
- Carnosol
Catalog No.:BCN1055
CAS No.:5957-80-2
- 3-Amino-2-naphthoic acid
Catalog No.:BCC8607
CAS No.:5959-52-4
- H-D-Gln-OH
Catalog No.:BCC2920
CAS No.:5959-95-5
Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.[Pubmed:6678857]
Invest New Drugs. 1983;1(1):65-70.
The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (3/13 responses in Hodgkin's; 9/37 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.
Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma.[Pubmed:1709152]
Invest New Drugs. 1991 Feb;9(1):53-7.
Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of pibenzimol for pancreatic tissue led us to conduct a phase I-II trial of pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of pibenzimol at a dose ranging from 6-28 mg/m2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.[Pubmed:20074267]
Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):497-504.
In pre-clinical studies, 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) is a weak DNA-intercalating, hypoxia-selective cytotoxin with a promising profile as an adjuvant to radio/chemotherapy and it is about to enter phase I clinical trials. The present investigation was undertaken to further evaluate potential systemic toxicity induced by i.v. doses of NLCQ-1 alone or in combination with Taxol in Sprague-Dawley rats, in support of an investigational new drug application. Doses of NLCQ-1 were based on previous range-finding studies. In the present study, NLCQ-1 was administered either alone, at 0, 6, 9 or 12 mg/kg/dose to male rats and 8, 12 or 16 mg/kg/dose to female rats or, at 9 (male rats) and 12 (female rats) mg/kg/dose, in combination with Taxol, on a qd x 5 schedule. Taxol was administered i.v. at 3.5 mg/kg/dose 1 hr before NLCQ-1. Observations were recorded for mortality/moribundity, clinical signs of toxicity, body weights, food consumption, haematology, clinical chemistry, gross lesions at necropsy and histopathology. Blood samples were taken from 10 animals from each dose group on each of 2 days (days 8 and prior to scheduled necropsy on day 33). Administration of i.v. doses of NLCQ-1 alone, on a qdx5 schedule, resulted in no signs of toxicity over the 33-day study. Taxol-induced toxicity included minimal decreases in the group mean RBC, haemoglobin and haematocrit values, minimal increases in group mean reticulocyte counts (females), marked decreases in group mean neutrophil counts and minimal decreases in group mean monocyte and eosinophil counts. Lymphoid atrophy of thymus, atrophy of bone marrow and atrophy of the germinal epithelium of the testis were also associated with the administration of Taxol. There was no additional toxicity associated with the co-administration of NLCQ-1 and Taxol. In the present study, the 'no observable adverse effect level' for NLCQ-1, when administered on a qdx5 schedule, was >12 and >16 mg/kg/dose in male and female rats respectively. Daily administration of 9 (male rats) or 12 (female rats) mg/kg of NLCQ-1 1 hr after i.v. administration of Taxol (3.5 mg/kg) had no effect on Taxol-induced toxicity.
Investigational new drug-directed toxicology and pharmacokinetic study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) in Beagle dogs.[Pubmed:20074266]
Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):511-22.
4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a 2-nitroimidazole-based hypoxia-selective cytotoxin has been shown to target hypoxic regions of solid tumours. The present study is one of several pre-clinical toxicology studies conducted in support of an 'investigational new drug' (IND) application to test this agent as an adjuvant to radio/chemotherapy for the treatment of cancer in humans. Twenty-four dogs were each assigned to one vehicle control group or to one of three test article-treated groups (three dogs/sex/treatment group). Intravenous (i.v.) doses of 0, 2.74, 5.48 and 10.95 mg/kg/day (54.8, 109.6 or 219 mg/m(2)/day) were administered on a per day x 5 days (qd x 5) schedule. NLCQ-1 was formulated as a solution in sterile saline at 1.5 mg/ml. None of the dogs died during this 33-day study. With few exceptions, most of the clinical signs of toxicity were noted within 2 hr following dosing in the 10.95 mg/kg/day dose group. These observations included aggressive behaviour, ataxia, tachypnea, emesis, hypoactivity, excessive salivation, tremors, and involuntary urination and defecation. Aggressive behaviour was judged to be dose-limiting. No clinical signs of toxicity were noted during the 28-day observation period that followed the 5-day dose period. Findings in a functional observation battery examination were consistent with the clinical observations. No drug-related effects were noted on the body weight or food consumption values, and no drug-related changes were noted during ocular examinations made on these animals prior to scheduled necropsy or during examination of electrocardiogram recordings made at 15 min. and 2 hr after dosing on days 1 and 5. No definitive changes in haematology, clinical chemistry or coagulation values were noted in dogs treated with NLCQ-1. NLCQ-1 was detected in the plasma of treated dogs on days 1 and 5, up to 60 min. after dosing (2.74 and 5.48 mg/kg/day) and up to 8 hr after dosing (10.95 mg/kg/day). There was a dose-related increase in maximum plasma concentration of NLCQ-1 at 5 min. after dosing; comparable concentrations were noted on days 1 and 5. No definitive test article-related lesions were noted during microscopic evaluation of tissues from dogs in this study, although lesions noted at the injection site and in the vascular tissue, lungs, thymus, prostate gland, muscle, adrenal cortex and tongue may have resulted from treatment with this drug. Any drug-related toxicity noted was readily reversible and not cumulative. No sex difference was detected in the susceptibility to NLCQ-1-induced toxicity.
Pilot screening programme for small molecule activators of p53.[Pubmed:15729694]
Int J Cancer. 2005 Jul 10;115(5):701-10.
Activation of the p53 tumour suppressor is predicted to have therapeutically beneficial effects. Many current anti-cancer therapies activate the p53 response via DNA damage. Non-genotoxic activation of the p53 pathway would open the way to long-term and possibly prophylactic treatments. We have established a simple protocol to screen small compound libraries for activators of p53-dependent transcription, and to select and characterise the most interesting hits, which include non-genotoxic activators. These compounds or their derivatives are of potential clinical interest. This approach may also lead to the identification of novel p53-activating compound families and possibly to the description of novel molecular pathways regulating p53 activity.
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.[Pubmed:12676586]
Cancer Cell. 2003 Mar;3(3):285-96.
We used synthetic lethal high-throughput screening to interrogate 23,550 compounds for their ability to kill engineered tumorigenic cells but not their isogenic normal cell counterparts. We identified known and novel compounds with genotype-selective activity, including doxorubicin, daunorubicin, mitoxantrone, camptothecin, sangivamycin, echinomycin, bouvardin, NSC146109, and a novel compound that we named erastin. These compounds have increased activity in the presence of hTERT, the SV40 large and small T oncoproteins, the human papillomavirus type 16 (HPV) E6 and E7 oncoproteins, and oncogenic HRAS. We found that overexpressing hTERT and either E7 or LT increased expression of topoisomerase 2alpha and that overexpressing RAS(V12) and ST both increased expression of topoisomerase 1 and sensitized cells to a nonapoptotic cell death process initiated by erastin.